From: Prediction of resistance to chemotherapy in ovarian cancer: a systematic review
Study | Prediction | Sensitivity | Specificity | LR+ve†| LR-ve†| P(C+)†| P(C−)†| P(C+|T+)†| P(C+|T−)†|
---|---|---|---|---|---|---|---|---|---|
Li et al. [3] | Chemoresistance | 0.96* | 0.23* | 1.24 | 0.18 | \(\frac {22}{44}\) | \(\frac {22}{44}\) | 0.55 | 0.15 |
Obermayr et al. [27] | RFS | 0.22* | 0.85* | 1.47 | 0.92 | \(\frac {46}{216}\) | \(\frac {170}{216}\) | 0.28 | 0.77 |
Ferriss et al. [33] | Chemoresponse | 0.94* | 0.29* | 1.33 | 0.20 | \(\frac {85}{119}\) | \(\frac {34}{119}\) | 0.77 | 0.07 |
Sabatier et al. [37] | Prognosis | 0.62* | 0.62* | 1.64 | 0.62 | \(\frac {194}{366}\) | \(\frac {172}{366}\) | 0.65 | 0.35 |
Yoshihara et al. [43] | PFS | 0.64* | 0.69* | 2.06 | 0.52 | \(\frac {45}{87}\) | \(\frac {39}{87}\) | 0.69 | 0.30 |
Williams et al. [44] | Prognosis | 0.77* | 0.56* | 1.75 | 0.41 | \(\frac {97}{143}\) | \(\frac {46}{143}\) | 0.79 | 0.16 |
Gevaert et al. [49] | Chemoresistance | 0.67* | 0.40* | 1.12 | 0.82 | \(\frac {15}{45}\) | \(\frac {30}{45}\) | 0.36 | 0.62 |
Helleman et al. [53] | Chemoresistance | 0.89* | 0.56* | 2.02 | 0.20 | \(\frac {9}{72}\) | \(\frac {63}{72}\) | 0.22 | 0.58 |
De Smet et al. [52] | Chemoresistance | 0.71†| 0.83†| 4.29 | 0.34 | \(\frac {6}{13}\) | \(\frac {7}{13}\) | 0.79 | 0.29 |
Raspollini et al. [56] | Prognosis | 0.79†| 0.46†| 1.45 | 0.47 | \(\frac {28}{52}\) | \(\frac {24}{52}\) | 0.63 | 0.29 |
Hartmann et al. [57] | Prognosis | 0.86* | 0.86* | 6.14 | 0.16 | \(\frac {21}{28}\) | \(\frac {7}{28}\) | 0.95 | 0.05 |
Selvanayagam et al. [59] | Chemoresistance | 1.00†| 1.00†| ∞ | 0.00 | \(\frac {4}{8}\) | \(\frac {4}{8}\) | 1.00 | 0.00 |
Kamazawa et al. [61] | Chemoresponse | 1.00* | 0.83†| 6.00 | 0.00 | \(\frac {21}{27}\) | \(\frac {5}{27}\) | 0.95 | 0.00 |